A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals' dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD's dTpa-IPV vaccine (Repevax), when coadministered with GSK Biologicals' MMR vaccine (Priorix) in 3 and 4-year-old healthy childrens

Trial Profile

A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals' dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi Pasteur MSD's dTpa-IPV vaccine (Repevax), when coadministered with GSK Biologicals' MMR vaccine (Priorix) in 3 and 4-year-old healthy childrens

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs DTaP poliovirus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix); Measles mumps and rubella virus vaccine-(Priorix)
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 22 Jun 2012 Actual paient number changed from 390 to 388 as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual paient number changed from 384 to 390 as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top